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Background
Bipolar disorder is a common mental disorder. Type I and
type II have a prevalence rate of up to 3.7% and both are
disabling conditions. Their aims to the resolution of
symptoms, restoration of psychosocial functioning and
prevention of relapse. The development of treatment
guidelines emerged as an important element so as to
standardize treatment and to provide clinicians with algo-
rithms, which would be able to carry research findings to
the everyday clinical practice.
Materials and methods
The MEDLINE was searched with the combination of each
one of the key words 'mania','manic','bipolar', 'manic-
depression','manic-depressive' with 'treatment guide-
lines'.
Results
The search was updated until October 1st, 2003 and
returned 204 articles. The review process based on the
titles and abstracts selected 84 of them as relevant to
include in the current study. Among them there were 26
papers concerning structured treatment algorithms pro-
posed by official panels.
Discussion
The American Psychiatric Association and the Texas Con-
sensus Conference Panel on Medication Treatment of
Bipolar Disorder are the most up-to date guidelines. The
core proposal of these guidelines is that all bipolar
patients should receive continuous treatment with an
antimanic agent with an intermittent use of antidepres-
sants. At the first stage of the mania/hypomania algo-
rithm, monotherapy with lithium, divalproex sodium or
olanzapine is recommended. At latter stages combination
therapy is strongly recommended. It is clearly stated that
in bipolar depression antidepressants should be used only
in combination with antimanic agents in order to avoid
switching of phases. During the maintenance phase all
patients should receive antimanic agents, while some will
need the addition of antidepressants.
Conclusion
The more recent guidelines point the value of atypical
antipsychotics and particularly of olanzapine in the treat-
ment of bipolar disorder as equal to that of mood stabiliz-
ers.
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